Ironwood Pharmaceuticals Inc. says it is on track to start selling a treatment for chronic constipation and irritable bowel syndrome in adults, following Thursday’s approval by the Food and Drug Adminstration.

The highly anticipated pill, called Linzess, will be the first product developed by the 14-year-old Cambridge company to hit the market. The FDA approval was expected, but most observers had predicted it would come next month.